Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
Key Highlights
- ➤Squamous cohort ORR 72.4%, DCR 100% after 12.7 months’ median follow-up
- ➤Squamous cohort median duration of response reached 12.9 months
- ➤Pooled efficacy produced 63.1% ORR and 89.2% DCR at 17.2 months’ follow-up
- ➤Grade 3+ treatment-related adverse events affected 48.6% of participants
- ➤TeLuRide-008 interim dose-selection analysis expected in 2H 2027
Expert Statements
Roy Baynes, Chief Medical Officer of Eikon Therapeutics
“These updated results presented at ESMO from the squamous NSCLC cohort build on the mature non-squamous cohort data presented at ASCO and further support the potential of adding EIK1001 to pembrolizumab and chemotherapy.”
Roy Baynes, Chief Medical Officer of Eikon Therapeutics
“The observed response and disease control rates, as well as a 12.9-month median duration of response, are encouraging, with several patients remaining in active follow-up.”
Roy Baynes, Chief Medical Officer of Eikon Therapeutics
“These findings support continued evaluation of this combination for patients with advanced NSCLC.”
* TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile supportive of systemic administration in an outpatient setting * With median follow-up of 12.7 months, objective response rate (ORR) for the squamous cohort was 72% and disease control rate (DCR) was 100%, with a median duration of response of 12.9 months and multiple participants continuing in active follow-up * TeLuRide-008, an ongoing adaptive Phase 2/3 trial of EIK1001 in NSCLC, actively enrolling, with a prespecified interim analysis for dose selection anticipated in 2H 2027 MILLBRAE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the presentation of updated data for EIK1001 at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.
Get started
Create a free account to read the full story.